WASHINGTON (Reuters) - Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the ...

AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to Bydureon (exenatide 2 mg powder and ...

(Reuters) - AstraZeneca said on Friday its once-weekly diabetes medicine Bydureon was approved in the United States for use in patients as young as age 10, expanding the drug's access to a critical ...

With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...

UAE, Dubai - 13 November 2011 - Eli Lilly and Company, together with the Ministry of Health (MOH) in the UAE , announced today that Bydureon® (exenatide for prolonged release suspension for injection) ...

Bristol-Myers Squibb and AstraZeneca have completed their deal with Eli Lilly to take over the commercialisation of diabetes drug exenatide - in the forms Byetta and Bydureon - in the UK.